Behind Cuba's successful pandemic response.
Behind Cuba's successful pandemic response.
复制标题
DOI：
10.1016/s1473-3099(21)00159-6
复制
发表时间：
2021-04
期刊：
影响因子：
--
通讯作者：
Burki T
中科院分区：
文献类型：
--
作者：
Burki T
在《柳叶刀传染病》付印之际，古巴将启动针对COVID-19的亚单位结合疫苗的3期试验。Soberana-2是古巴正在开发的四种候选COVID-19疫苗之一。它是由哈瓦那的芬利研究所制作的。根据尚未公布的早期临床试验结果，芬利研究所所长维森特·韦雷兹-本科莫预计，该疫苗的有效性将达到80- 95%。“我们非常乐观，”他说。如果一切按计划进行，古巴可能会在夏季的某个时候为其1120万公民启动大规模疫苗接种计划。在2020年的大部分时间里，古巴都在遏制SARS-CoV-2，但在2021年，古巴的感染人数激增。截至3月8日，该国已报告55693例COVID-19病例和348例死亡。仅2月份就发生了23093例新病例，几乎是2020年全年的两倍。古巴的情况仍然比该地区大多数其他国家好得多，但迫切需要疫苗。
As The Lancet Infectious Diseases went to press, Cuba was due to launch a phase 3 trial of its subunit conjugate vaccine against COVID-19. Soberana-2 is one of four candidate COVID-19 vaccines in development in Cuba. It is produced by the Finlay Institute in Havana. On the basis of as-yet-unpublished results from early-stage clinical trials, Vicente Verez-Bencomo, director-general of the Finlay Institute, expects the vaccine to show an efficacy in the region of 80–95%.“We are very optimistic”, he said. If everything goes according to plan, Cuba could start a mass vaccination programme for its 11· 2 million citizens sometime in the summer.After keeping SARS-CoV-2 at bay for most of 2020, Cuba has experienced a surge of infections in 2021. As of March 8, the country had reported 55 693 cases of COVID-19 and 348 deaths. 23 093 new cases occurred in February alone, almost twice as many as occurred in the whole of 2020. Cuba is still doing far better than the majority of other countries in the region, but a vaccine is urgently needed.